---
trial_id: 265
discovery_date: 2022-03-29 21:28:28.044833
date: 2022-03-29 21:28:28.044833
title: "An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physicianâ€™s choi..."
summary: |
  <p>EudraCT Number: 2020-004505-32<br />Sponsor Protocol Number: COMB157G3301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-06-09<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/IT">IT</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004505-32'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2020-004505-32<br />Sponsor Protocol Number: COMB157G3301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-06-09<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/FR">FR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/IT">IT</a> (Ongoing)</p>